IP Library Granted Patent US 8,481,550
Granted Patent B2
US 8,481,550 · App. 13/216,352 · Granted Jul 9, 2013

Heteroaryl compounds useful as inhibitors of E1 activating enzymes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,550
App. No.
13/216,352
Granted
Jul 9, 2013
Kind
B2
Abstract

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

Claims (34)

1. A method for treating lung cancer or colorectal cancer in a patient in need thereof, comprising administering to the patient a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

X is —NH— or —O—;

R a is hydrogen or —OH;

R c is hydrogen or —OH;

W is —NH—, —N(R 1 )— or —O—, wherein R 1 is C 1-4 aliphatic;

one of D and E is —N═ and the other is —C(R h )═;

each R h is independently hydrogen, halo or C 1-4 aliphatic;

R 8 is hydrogen or C 1-4 aliphatic;

each R p is independently halo or C 1-4 aliphatic;

each R 8p is independently halo; C 1-4 aliphatic optionally substituted with —OR 5x or —C(O)—N(R 4x )(R 4y ), wherein R 5x is hydrogen or C 1-4 alkyl, R 4x is hydrogen or C 1-4 alkyl, and R 4y is hydrogen or C 1-4 alkyl; —OR 5x wherein R 5x is hydrogen or C 1-4 alkyl; or —C(O)—N(R 4x )(R 4y ) wherein R 4x is hydrogen or C 1-4 alkyl and R 4y is hydrogen or C 1-4 alkyl;

s is 0, 1 or 2; and

t is 0, 1 or 2.

2. The method of claim 1 , wherein the compound is administered orally.

3. The method of claim 1 , wherein the compound administered to the patient in need thereof is:

or a pharmaceutically acceptable salt thereof, wherein:

R a is hydrogen or —OH;

R p is hydrogen or —OH;

W is —NH— or —O—;

each R p is independently halo or C 1-4 aliphatic;

each R 8p is independently halo; C 1-4 aliphatic optionally substituted with —OR 5x or —C(O)—N(R 4x )(R 4y ), wherein R 5x is hydrogen or C 1-4 alkyl, R 4x is hydrogen or C 1-4 alkyl, and R 4y is hydrogen or C 1-4 alkyl; —OR 5x wherein R 5x is hydrogen or C 1-4 alkyl; or —C(O)—N(R 4x )(R 4y ) wherein R 4x is hydrogen or C 1-4 alkyl and R 4y is hydrogen or C 1-4 alkyl;

s is 0, 1 or 2; and

t is 0, 1 or 2.

4. The method of claim 3 , wherein W is —O—.

5. The method of claim 3 , wherein each R p is independently —F or —Cl.

6. The method of claim 3 , wherein each R p is independently halo; and each R 8p is independently C 1-4 aliphatic or —OR 5x wherein R 5x is hydrogen or C 1-4 alkyl.

7. The method of claim 1 , wherein X is O.

8. The method of claim 1 , wherein W is NH or O.

9. The method of claim 1 , wherein each R h is independently hydrogen, halo or CH 3 .

10. The method of claim 1 , wherein R 8 is hydrogen.

11. The method of claim 3 , wherein W is NH.

12. The method of claim 3 , wherein each R p is independently halo.

13. The method of claim 3 , wherein each R 8p is independently C 1-4 aliphatic or OR 5x wherein R5x is hydrogen or C 1-4 alkyl.

14. The method of claim 13 , wherein each R 8p is independently CH 3 or OCH 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056729/0503 →